Back to top
more

NuVasive, Inc. (NUVA)

(Delayed Data from NSDQ)

$62.96 USD

62.96
567,418

+0.74 (1.19%)

Updated May 3, 2019 04:00 PM ET

After-Market: $62.96 (%) 5:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

NA

Industry: NA

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Phibro's (PAHC) Q1 Earnings & Revenues Fall Y/Y, Margins Down

by Zacks Equity Research

Phibro (PAHC) exhibits a dismal first-quarter performance on a decline in revenues at core business segments.

NUVA vs. RMD: Which Stock Should Value Investors Buy Now?

by Zacks Equity Research

NUVA vs. RMD: Which Stock Is the Better Value Option?

Zimmer Biomet (ZBH) Q3 Earnings Top, Operating Margin Falls

by Zacks Equity Research

Zimmer Biomet (ZBH) gains from strong sales growth across all geographies and most operating segments in Q3.

Hill-Rom's (HRC) Q4 Earnings Beat on Strong Global Sales

by Zacks Equity Research

Internationally, Asia Pacific, Latin America and EMEA registers strong revenue growth for Hill-Rom (HRC).

Tandem Diabetes (TNDM) Q3 Loss Narrows Y/Y, Sales Improve

by Zacks Equity Research

Tandem Diabetes (TNDM) exhibits a robust performance in the third quarter of 2019, fueled by strong domestic demand.

Intersect ENT (XENT) Reports Q3 Loss, Revenues Meet Estimates

by Zacks Equity Research

Intersect ENT (XENT) exhibits a dismal performance in the third quarter of 2019.

Haemonetics (HAE) Beats on Q2 Earnings, Raises '20 EPS View

by Zacks Equity Research

Haemonetics (HAE) delivers robust fiscal second-quarter revenues, fueled by strong performances in Plasma and Hospital segments.

Syneos Health (SYNH) Tops Q3 Earnings Estimates, Ups EPS View

by Zacks Equity Research

Syneos Health (SYNH) exhibits robust topline performance in the third quarter, backed by strong segmental growth.

Bruker (BRKR) Beats Q3 Earnings Estimates, Ups EPS Guidance

by Zacks Equity Research

Bruker (BRKR) delivers robust third-quarter revenue growth, backed by strong segmental performances.

NuVasive (NUVA) Earnings and Revenues Beat Estimates in Q3

by Zacks Equity Research

We are encouraged to note that NuVasive (NUVA) witnessed solid revenue growth across its U.S. Spinal Hardware business in Q3.

NuVasive (NUVA) Q3 Earnings and Revenues Beat Estimates

by Zacks Equity Research

NuVasive (NUVA) delivered earnings and revenue surprises of 9.26% and 2.54%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?

Medical Products' Oct 30 Earnings Roster: MCK, MASI & More

by Zacks Equity Research

Despite the ongoing US-China trade war, solid growth in emerging markets is likely to have driven the performance of the players in the medical products space this earnings season.

Earnings Preview: NuVasive (NUVA) Q3 Earnings Expected to Decline

by Zacks Equity Research

NuVasive (NUVA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Urmimala Biswas headshot

Medtronic Submits Two Pelvic Health Devices for FDA's PMA

by Urmimala Biswas

Medtronic's (MDT) filing for both its InterStim products to gain FDA's PMA is its essential bid to boost its Pelvic Health & Gastric Therapies business.

Omnicell Advances on Global Footing Despite Severe Rivalry

by Zacks Equity Research

Considering the weak penetration level in the international market, which is even less than 1%, Omnicell (OMCL) is rapidly exploring the uncharted overseas markets.

Medtronic (MDT) Gets FDA Nod to Study Intrepid TMVR System

by Zacks Equity Research

The FDA clearance is expected to boost Medtronic's (MDT) structural heart business.

NuVasive Announces Innovations in Robotics Spine Surgery Line

by Zacks Equity Research

NuVasive (NUVA) aims to speed up the adoption of less invasive spine surgery through robotics.

Here's Why You Should Hold GNC Holdings (GNC) Stock for Now

by Zacks Equity Research

Investor confidence continues to be high in GNC Holdings (GNC), thanks to solid prospects.

Integra Buys Rebound Therapeutics to Boost Neurosurgery Line

by Zacks Equity Research

Integra (IART) believes, Rebound's MIS technological arm will widen its neurosurgical pipeline within Codman Specialty Surgical space.

GNC Holdings Rides on New Pacts Amid Weak Same Store Sales

by Zacks Equity Research

GNC Holdings' (GNC) recent joint venture with vitamins and nutritional supplement manufacturer International Vitamin Corporation shows high prospects at present.

Medtronic's (MDT) MiniMed 670G Gains German Reimbursement

by Zacks Equity Research

Medtronic's (MDT) MiniMed 670G is witnessing a solid uptake in the United States ever since its launch last year.

Illumina Banks on New Product Suite Despite Margin Woes

by Zacks Equity Research

The unveiling of Veriseq NIPT v2 and Illumina's (ILMN) alliance with AnchorDx in the second quarter further raise investor confidence in the stock.

Abbott (ABT) Launches Pivotal Trial TRILUMINATE in the US

by Zacks Equity Research

Given the lack of an alternative therapy to replace tricuspid regurgitation surgery, Abbott (ABT) should be at an advantage in this space.

Edwards Lifesciences Hits a 52-Week High on Solid Prospects

by Zacks Equity Research

Edwards Lifesciences (EW) gains from recent impressive developments.

Here's Why You Should Invest in Amedisys (AMED) Right Now

by Zacks Equity Research

Amedisys (AMED) is currently enjoying investors' confidence, thanks to solid prospects.